Glycation and fluorescence at 440 nm (excitation at 370 nm) were found to be increased in immunoglobulin G (IgG) from diabetics, strongly indicating the presence of IgG-linked advanced glycosylation end products. In contrast, levels of IgG-linked advanced glycosylation end products were low or undetectable in both normal and diabetic subjects when an advanced glycosylation end products specific antibody was employed for immunological determination of advanced glycosylation end products. Furthermore, no correlation exists between IgG glycation, fluorescence and immunoreactivity. In diabetics, the Fc fragment of IgG showed decreased protein A binding and decreased fixation of complement. This impairment of biological activity was not correlated with the immunologically determined level of advanced glycosylation end products, whereas IgG-linked fluorescence was inversely related to complement fixing activity. TTiese results indicate that mechanisms different from glycation or browning are respoüsible for changes in the functional properties of IgG.
Introduction
In glycation, glucose reacts with free amino groups of proteins to form labile Schiff bases, which subsequently undergo Amadori rearrangemerit to stable ketoamines. Formation tfAmädori products is well established for a number of proteins and häs been found to be increased in diabetes (föf a review see 1. c. (1)). The Amadori product undergoes veiy slowly a seiies of still unknown reâ rrangement reactions to form yellow-brpwn, flüorê scent and cross^linking substänces, called advanced glycosylation end products. These bro\^ning products are thought to accumulate on proteins and to play an irnportaiit role in the development of diabetic late complications (for ä review see 1. c. (2) ).
Our recent studies indicate that glycation of immunoglobulin G (IgG) in vitro leads to IgG fluorescence and polymerization (3) , concomitant with marked changes in functional properties of the Fc fragment (4, 5) . In view of the possible pathophysiological relevance of these findings, we examined the biological activity of the Fc fragment of IgG from normal and diabetic subjects. thermore, the possible involvement of IgG-linked advanced glycosylation end products was investigated with the aid of an advanced glycosylation end products specific enzyme-linked immunosorbent assay (ELISA). Evidence is presented, indicating that the Fc fragment pf IgG from diabetics is fimctionally impaired, and that this impairment is unrelated to glycation or formation of advanced glycosylation end products.
Materials and Methods

Materials
Bövine serum albumin, sheep blood and amboceptor 6000 were from Behringwerke, Marburg/Lahn, Germany. The Glyco-Gel B Test Kit was from Pierce, Oud-Beijerland, The Netherlands; the enzyme immunoassay for determination of human IgG subclasses from The Binding Site, Birmingham, U. K.; DEAE-cellulose (DE-52) from Whatman BioSystems, Maidstone, U.K.; keyhole limpet haemocyanin frorn Calbiochem, Bad Soden, Germany; peroxidaselinked sheep anti-rabbit IgG from Boehringer, Mannheim, Germany. All other chemicals were from Sigma, Deisenhofen, Germany, or from E. Merck, Darmstadt, Germany.
Methods
Serum was obtained from 43 normal healthy persons (ranging betwcen 21 and 58 years of age) and from 43 diabetic patients (17-75 years old) attending thc outpatient Service for diabetic care of the Hospital München-Schwabing, an Academic Hospital of the University of Munich. Patients were included irrespective of type of treatment. Informed consent was obtained from all subjects before venepuncture.
Immunoglobulin G from human serum was purified by precipitation with (NH^SC^ and chromatography on DEAE-cellulose, äs previously described (4) . The purification procedure yielded highly purified IgG preparations äs revealed by polyacrylamide gel electrophoresis, sodium dodecyl sulphate polyacrylamide gel eleo trophoresis and immunoelectrophoresis.
IgG was quantified in a Beckman Array protein System or by measurement of absorbance at 280 nm. Human IgG subclasses l, 3 and 4 were determined by enzyme immunoassay according to the supplier's instructions. The level of glycated IgG in percentage of total IgG was measured by affmity chromatography (6) using the Glyco-Gel B test kit. IgG (2 mg) was applied to the top of an aminophenylboronic acid column and further processed according to the supplier's instructions. Absorbance of bound and unbound fractions was determined at 280 nm in a Shimadzu UV-260 spectrophotometer.
Advanced glycosylation end products were estimated by measurement of IgG absorbance at 350 rim (7, 8) at a protein concentration of l g/l in a Shimadzu UV-260 spectrophotometer. In addition, IgG-linked fluorescence at 440 nm upon excitation at 370 nm (7, 8) was determined at an IgG concentration of 0.5 g/l in an AmincoBowman spectrofluorometer. Absorbance at 350 rim and relative fluorescence were expressed relative to the absorbance at 280 nm.
Advanced glycosylation end product proteins (derived from human albumin, human IgG, human transferrin, bovine albumin and bovine globulin) were prepared in vitro by incubating 43.3 >1/1 of the respective protein for 34 days at 37 °C with 55.5 mmol/1 glucose in 0.05 mol/1 2-amino-2-methyl-propanol-(l) buffer, pH 9.5, containing 1.2 mmol/1 MgSO 4 , 5.4 mmol/1 KC1, 26.2 mmol/1 NaHCO 3 , 116 mmol/1 NaCl, 6 mmol/1 NaN 3 and 10 mg/1 gentamicin, followed by dialysis against 154 mmol/1 NaCl. Poly-L-lysine (M r 15 000 to 30 000) (5 g/l) was incubated at 37 °C in the presence of l .67 mol/1 glucose for 18 days in 2-amino-2-methyl-propanol-(1) buffer.
Advanced glycosylation end products were detected immunochemically essentially äs described by Nakayama et al. (9, 10) . Briefly, keyhole limpet haemocyanin (20 g/l) was incubated under sterile conditions in the absence and presence of 2.2 mol/1 glucose at 37 °C in 0.4 mol/1 Na-phosphate buffer, pH 7.5, for twelve weeks. After extensive dialysis against 154 mmol/1 NaCl, rabbits were immunized with l mg advanced glycated and non-glycated keyhole limpet haemocyanin, respectively, emulsified in incomplete Freundes adjuvant, followed by 7 booster injections at 2-week intervals.
Antisera titres were determined in a non-competitive ELISA. Wells of microtitre plates (Nunc immunoplates) were coated ovemight at 4 °C with 0.1 ml of advanced glycosylation end products protein, 0.5 mg/1 in 0.1 mol/1 carbonate buffer, pH 9.6. The wells were washed with 154 mmol/1 NaCl containing 0.5 ml/l Tween 20, then blocked with 5 g/l bovine serum albumin in phosphate-buffered saline, pH 7.4. Rabbit antisera dilutions (0.1 ml) were added to the wells and incubated for two hours at room temperature. Thereafter, wells were washed again and developed with a peroxidase-conjugated anti-rabbit IgG from sheep, using o-phenylenediamine äs Substrate. Absorbance at 450 nm was read on a Microplate reader MR 6000 (Dynatech).
IgG-linked advanced glycosylation end products were assayed in a competitive ELISA. Microtitre plates were coated by adding 0.1 ml human advanced glycosylation end products IgG, 0.5 mg/1, in 0.1 mol/1 carbonate buffer, pH 9.6. After incubation overnightj wells were washed and blocked with 0.2 ml 5 g/l bovine serum albumin in phosphate buffered saline, pH 7.4. Thereafter, 0.05 ml of samples (IgG, 2 g/l) and 0.05 ml of l : 1000 diluted rabbit antiserum were added to the wells. Plates were incubated for 2 hours at room temperature and overnight at 4 °C, and further processed äs described for the non-competitive assay. A calibration curve was prepared from serial l : 2 dilutions of human advanced glycosylation end products IgG, corresponding to IgG protein concentrations of 200 to 3. l mg/1. Relative fluorescence of the respective dilutions ranged frorri 2 to 0.03-Immunoreactivity of samples was read from the calibration curve and was expressed äs advanced glycosylation end products units, one advanced glycosylation end products unit corresponding to the ariipunt of antibody-reactive material found in Standard advanced glycosylation end products IgG at a protein concentration of l mg/1 (l advanced glycosylation end products unit = l mg/1 advanced glycosylation end products IgG protein). The calibration curve was linear frorh 6 to 100 advanced glycosylation end products units. Determinations were run in triplicate. The intra-assay coefflcient of Variation was 7.1% (je = 118 advanced glycosylation end products units, n= 16), while the inter-assay coefficient of Variation was 10.8% (X = 23 advanced glycosylation end products units, n = 31) and 12% (X = 7.4 advanced glycosylation end products units, n = 28).
Protein A reactivity arid complement (C) fixation were determined äs described previously (5) . Statistical evaluation was perfbrrned according to the instructions of Sachs (11) . Statistical significance was calculated by Studenfs tatest for unpaired data. Results are given äs mean values ± SD.
Results
Immunoglobulin G was prepared from sera from 43 non-diabetic apparently healthy subjects, äs well äs from 43 diabetic patients displaying mean HbA lc levels of 5% (ränge 3.9%-5.6%) and 9% (ränge 4.6%-13.7%), respectively. The IgG concentration was found to be essentially the same in normal and diabetic sera (10.6 ± 1.9 g/l and 10.7 ± 2.3 g/l). Furthermore, IgG subclasses l, 3 and 4 were determined in the preparations. No difference in the content of IgG subclasses was observed.
Levels of glycated IgG were found to be markedly increased in diabetic patients äs revealed by affinity chromatography on boronate gel. Expressed äs a percentage of total IgG (in analogy with HbA lc ), glycation amounted to 4.1 ± 0.87% (ränge 2.2%-5.7%, n == 43) and 10.3 ± 4.5% (ränge 2.9%-21.1%, n = 43, p < 0.0005) im normal and diabetic subjects, respectively. A clear correlation (r = 0.705) was demonstrable between HbA le and glycated IgG in diabetics (data -not shown).
The possible occurrence of protein-bound brown and/or fluofescent chromophores, indicäting the formation of advanced glycosylation end products (7, 8) , was investir gated by measurement of absorbanee at 350 nm and of fluorescence at 440 nm upon excitation at 370 nm. As revealed by determination of absorbance at 350 nm, IgG browning was essentially the same in normal and diabetic subjects, amounting to 3 % 6 ± 1.56 and 3.7 ± 1.98 (10 3 X A 350 nm/A280 nua^h = 15). In conträst, IgG Since browning products are not specifically assayed by measurement of fluorescence, antibodies against advanced glycated keyhole limpet haemocyanin were prepared essentially according to I.e. (9) . The properties and specificity of the antibody were very similar to those described by Nakayama et al. (9) for anti-advanced glycated keyhole limpet haemocyanin antibody, and by others, using advanced glycosylation end products derived from bovine serum albumin or from ribonuclease äs antigen (12, 13) . A non-competitive ELISA showed that antiserum from a rabbit immunized with advanced glycated keyhole limpet haemocyanin reacted with advanced glycosylation end products derived from human IgG, albumin, transferrin and from bovine albumin and globulin ( fig. 2) . A weak reaction was also observed with unmodified proteins, indicating the presence of low amounts of advanced glycosylation end products structures in native proteins, generated from in vivo glycated proteins or during storage (14) . Neither advanced glycosylation end products proteins nor native proteins gave a reaction with antisera from rabbits immunized with keyhole limpet haemocyanin incubated in the absence of glucose.
To determine the specificity of the anti-advanced glycosylation end products antibody, unmodified proteins, ad- Microtitre plates were coated with 0.5 mg/1 advanced glycosylation end products human albumin. Competitors were added to the welis at the concentrations given on the abscissa and further processed in a competitive ELISA äs described in Materials and Methods. Results were expressed äs B/B 0 , where B is sample absorbance and BÖ is absorbance in the absence of competitor (total absorbance). Advanced glycosylation end products protein derived frorn (o) human albumin (O) human IgG (A) human transferrin ( ) bovine albumin (a) bovine globulin Nearly identical results were obtained when microtitre plates were coated with advanced glycosylation end products IgG: vanced glycosylation end products proteins and poly-Z,-lysine were tested in a competitive assay. Figure 3 shows ELISA competition curves for anti-advanced glycated keyhole limpet haemocyanin-antiserum. It can be seen that advanced glycosylation end products derived from human and bovine albumin showed the greatest inhibition, while the weakest Inhibition was shown by advanced glycosylation end products derived from human transferrin. The Inhibition curves of different advanced glycosylation end products proteins were parallel to each other. Microtitre plates were coated with 0.5 mg/1 advanced glycosylation end products derived from human albumin. Native human IgG (·) and IgG incubated with glucose for 3 (O), 9 (A), 18 ( ) and 34 (·) days, respectively, was added to the wells at the concentrations given on the abscissa and further processed in a competitive ELISA äs described in Materials and Methods. Nearly identical results were obtained when plates were coated with advaneed glycosylation end products derived from IgG.
Immunorogical reactivity of proteins glycated in vitro increased with the time of incubätion with ghicose (flg. 4). Furthermore, poly-£-lysine incubated with glucose showed marked Inhibition in competitive ELISA, while no competition for antibody binding was disceraible from the starting material or from poly-Z-lysine incubated withöut glucose ( fig. 5) . In ordef to establish whether Schiff bases or Amadori products are recog* nized by the antibody, advanced glycosylation end products proteins were reduced with NaBH 4 . After redüction, the immunoreaetivity of advanced glycosylation end products proteins remained essentially unchanged (data not shown), indicating that -eariy glycätion products, The relationship between fluorescence and immunoreactivity during in vitro incubation is shown in figure 6 . A time-dependent increase in fluorescence concomitant with an increase in immunoreactivity was observed in albumin samples incubated with glucose. It is noteworthy that an approximate twofold increase in fluorescence occurred in samples incubated without glucose, while no change in irnrn noreactivity was detected. In order to determine whether fluorescence of IgG from normal and diabetic subjects is related to IgG immunoreactivity, the protein-bound advanced glycosylation end produets content of purified IgG was examined in a competitive ELISA. Unexpectedly, IgG preparations contained only small amounts, if any, of immunologically reactive material ( fig. 7) , which was 3 to 5 times lower than expected from the measurement of IgGlinked fluorescence.
Furthermore, IgG-linked advanced glycosylation end products levels were found to be higher in normal controls than in diabetics. In 8 out of 38 normal subjects, and in 29 out of 38 diabetics, advanced glycosylation end products values were lower than the detection limit (6 advanced glycosylation end products units). Immunologically determined levels of IgG-linked advanced glycosylation end products were not correlated with glycated IgG or with IgG-linked fluorescence ( fig. 8) . In this connection, it is noteworthy that no immunologically reactive material could be detected in albumin purified from 5 normal and 5 diabetic sera, although these albumins showed high fluorescence at 440 nm upon excitation at 370 nm (data not shown).
In order to investigate possible functional changes of diabetic IgG, binding of protein A and complement fixation, both occurring within the Fc fragment of IgG, were rrieasured. In diabetics, a statistically significant decrease in protein A reactivity was observed; 53 μg (SD = 16.9, n = 40) and 45 μg (SD = 13.7, n = 41) of IgG were bound by 12.5 μg of protein A in normal and diabetic subjects, respectively (p < 0.0125). Finally, a complement fixation test revealed a decrease in complement fixing activity of IgG from diabetics. In normal controls, complement fixation amounted to 70 ±21% (n = 43), whereas in diabetics the mean value was found to be 59 ± 27% (n = 42, p < 0.025); in five out of 42 diabetics C'-fixation was almost abolished. This decrease in C'-fixation was apparently independent of the age of the patients, the IgG subclass content of the sample, the IgG concentration in serum, the level of blood glucose, cholesterol, triacylglycerols, HbA lc , glycated IgG, the absorbance at 350 nm, or the amount of immunologically determined advanced glycosylation end products. However, a relationship between C'-fixation and IgG fluorescence was observed in diabetic patients. It is evident from figure 9 that fluorescence and C'-fixation are inversely correlated. Using IgG from diabetics, it was found that C'-fixation values < 40%, between 40% and 80% and > 80% were ssoci ted with relative fluorescence values of 0.244 ± 0.062 (n = 7), 0.186 ± 0.061 (n = 14) and 0.15 ± 0.037 (n = 10), respectively. The difference between each group of diabetics is statistically significant (p < 0.05), whereas in normal controls no difference was discernible.
Discussion
Until recently, advanced glycosylation end products were estimated by indirect, non-specific assays such s measurement of the decrease in solubility (15), of resistance to heat denaturation (16) , of absorbance at 350 nm and of fluorescence at 440 nm upon excitation at 370 nm (7, 8) . Furthermore, 2-(2-furoyl)-4(5)-(2-furanyl> IH-imidazole (17, 18), 5-hydroxy-methyi-l-alkylpyrrole-2-carbaldehyde (pyiraline) (19) , imidazo [4,5-b] pyridinium (pentosidine) (20) and 3-deoxyfructose and 3-deoxyglucosone (21) were claimed to represent advanced glycosylation end products formed in vivo and to be present in human serum proteins and tissues. However, detection of single possible advanced glycosylation end products substances in vivo is difficylt and cumbersome, since a large number of different brpwning products is known (22) . Nakayama et al. (9) introduced an antibody for immunological detefmination of advanced glycosylation end products. An antibody of comparable specificity was prepared in our laboratory and used in the present study. This antibody recognizes epitopes which are formed in a time-dependent fashion during incubation of proteins and amino acids with glucose in vitro. These immunologically reactive structures display fluorescenee and browning and are not reducible by NaBH 4 , suggesting the formation of a commoii dvaneed glycosylation end products structure(s) by incu-bation of proleins or amino acids with glucose, whose nature, however, is not yet known. In this connection it is noteworthy that neither 2-(2-furoyl)-4(5)-(2-ftiranyl)-IH-imidazole nor pyrraline or pentosidine react with an antibody against advanced glycosylation end products proteins (9, 12, 13) .
From the results of the measurement of IgG-linked fluorescence, it was expeoted that the subsequently measured levels of immunologically reactive material in IgG preparations would lie well within the ränge of the calibration curve employed. However, immunoreactivity in IgG, äs well äs in albumin, was low or undetectable, being higher in normals than in diabetic subjects. This suggests that serum proteins, like IgG or albumin, contain little if any browning products. Possibly, advanced glycosylation end products cannot be formed in considerable amounts because of the short halflife of the serum proteins, or because advanced glycosylation end products serum proteins are rapidly cleared from the circulation by the advanced glycosylation end products re-; ceptor (23) . Further, the possibility exists that the epi-; tope(s) formed in vitro do not occur in vivo.
It seems reasonable to assume that the marked increase in fluorescence of IgG from diabetics is due to mechanisms other than glycation and browning. Fluorescence can result from the reaction between lipid peroxidation products and proteins (24) and from the oxidation of amino acids by free radicals (25, 26) . It is known that lipid peroxide levels are increased in diabetics (27, 28) . Furthermore, it has been demonstrated that early glycation products, Schiff bases and Amadori products, can generate free radicals (29) (30) (31) . In addition, äs shown by Wolffl Hunt and coworkers (32) (33) (34) , glucose itself can produce free radicals via auto^oxidation. From these reports one can conclude that an increase in free radicalmediated oxidation of proteins might occur in hyperglycaemic diabetics.
With respect to the biological activity of IgG from diabetics, to our knowledge we have shown for the first time that certain functional properties of the Fc region of IgG from diabetics are impaired, i. e. there is a decrease in binding of protein A and fixation of complement to the Fc fragment, which probably contributes to the increased susceptibility to infections, known to occur in poorly controlled diabetics (35) . The reasons for the changes in the functional properties are unknown. Interaction with protein A and fixation of complement depend on the integrity of the region 230 to 270 of the heavy chains (36) , allowing structural changes of the Fc fragment äs a prerequisite for complement binding. One might speculate that oxidation of amino acids in the Fc region by free radical mechanisms is responsible for damage of the complement binding site, leading to an alteration of biological activity.
The possibility that oxidative mechanisms rather than glycation or browning reaction might be responsible for the impaired Fc fragment function is supported by the fact that the changes in functional properties are not correlated with the degree of glycation of IgG, absorbance at 350 nm, or immunoreactivity, whereas an inverse relationship was found between IgG-linked fluorescence and complement fixing activity.
